What Genericon Pharma does

Genericon Pharma Gesellschaft m.b.H. is a privately held Austrian pharmaceutical company founded in 1986 and headquartered in Graz, specializing in the development, manufacturing, and distribution of generic medicines. Its portfolio spans multiple therapeutic categories, including cardiovascular, metabolic, neurology and psychiatry, urology, gastroenterology, pain, infections, and oncology. The company also markets over-the-counter (OTC) products (e.g., IbuAkut, DicloAkut, Niconex, Diosmin Genericon, antihistamines) and dietary supplements under the MULTI sub-brand (MULTIvitD3 Baby, MULTIvitDK, MULTIprosti, FOLMIT forte). Operations are supported by GMP/GDP-compliant manufacturing with an in-house quality control laboratory, and the company claims a 59% share of Austria's generics-capable market, distributing more than 11 million prescribed drug packages annually (approximately 13 million total packages in 2023).

The company's go-to-market is exclusively B2B through pharmacies in Austria and, via its wholly-owned Croatian subsidiary Genericon Pharma d.o.o., in Croatia. Genericon does not sell direct to consumers; instead, it serves prescribing physicians and dispensing pharmacists through dedicated login-restricted portals providing technical product information, package leaflets, and professional materials under the Austrian Medicines Act. The dolphin trademark is the company's signature brand mark across packaging, signaling quality, trust, and safety.

Genericon's revenue model is unit-sale-based, capturing cost-driven demand by offering bioequivalent alternatives to originator drugs at lower prices, with larger package sizes that reduce prescription fees for Austrian patients. The company holds no disclosed funding rounds and operates without identified external private-equity or venture backing, suggesting founder/owner-controlled ownership. Affiliated entities include a wholly-owned core operating subsidiary, +pharma arzenimittel gmbh. Awards include the GX Mirror Award (first place, three consecutive years, from IQVIA and the Austrian Pharmacists' Association), an Above-Average Employer Certificate (2019), and a Best Workplace Award (2023).

Name

Genericon Pharma

Legal name

Genericon Pharma Gesellschaft m.b.H.

Website

https://genericon.at

Company type

Private

Founded year

1986

Operating status

Operating

Headcount range

101–250 employees

Short description

Genericon Pharma is an Austrian private generic pharmaceutical manufacturer founded in 1986 that develops and distributes prescription generics, OTC medicines, and dietary supplements across multiple therapeutic areas, serving patients exclusively through pharmacy distribution in Austria and Croatia.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Small-Molecule Generics (Branded/Unbranded) (HLAIABAA)

akta.pro secondary industries

Oral Solid Dose (OSD) Generics (HLAIABAD), Complex Generics (e.g., inhalation, transdermal, liposomal) (HLAIABAB), Generic Hospital & Institutional Products (HLAIABAL)

Keywords

• Generic pharmaceuticals
• Prescription medicines
• Over-the-counter drugs
• Dietary supplements
• Austrian healthcare

Headquarters

HQ city

Graz

HQ country

Austria

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Prescription generic drugs: Revenue from selling prescription generic pharmaceutical products across therapeutic areas including cardiovascular, metabolic, neurological, psychiatric, urological, gastroenterological, pain, and anti-infective medications. Products are sold through pharmacy channel partners.
2. Over-the-counter medications: Revenue from OTC products sold exclusively through pharmacies including IbuAkut, Diosmin Genericon, Niconex, DicloAkut, Ibucomp, Ambroxol, ASS, Paracetamol, Cetirizine, Levocetirizine, and Desloratadin products.
3. Dietary supplements (MULTI brand): Revenue from dietary supplement products under MULTI brand including MULTIvitD3 Baby, MULTIvitDK, MULTIprosti, and FOLMIT forte. Available without prescription in pharmacies.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

Genericon Pharma develops, manufactures, and distributes high-quality generic pharmaceutical products (prescription medicines, OTC medicines, and dietary supplements under the MULTI brand) across therapeutic areas including cardiovascular, metabolic, neurology and psychiatry, urology, gastroenterology, pain, anti-infective, and oncology. Products are manufactured under GMP/GDP standards with in-house batch testing, sold exclusively through pharmacies in Austria and Croatia.

Product overview

Genericon Pharma is an Austrian pharmaceutical company founded in 1986, specializing in the development and distribution of high-quality generic drugs. Its portfolio encompasses three main categories: (1) prescription generic medicines covering therapeutic areas of cardiovascular, metabolic, neurology and psychiatry, urology, gastroenterology, pain/infections, and oncology; (2) over-the-counter (OTC) medicines available exclusively in pharmacies, including IbuAkut, DicloAkut/DicloAkut forte, Diosmin Genericon, Niconex, Ibucomp, Ambroxol Genericon, antihistamines (Cetirizin, Levocetirizin, Desloratadin), ASS Genericon, and Paracetamol Genericon; and (3) dietary supplements under the MULTI sub-brand (MULTIvitD3 Baby, MULTIvitDK, MULTIprosti, FOLMIT forte). The company distributes over eleven million prescribed drug packages per year in Austria, making it one of the leading generics companies in the country. Supporting services include online health calculators (calorie, BMI, PSA doubling time), a menu timetable dietary planner, a downloadable instructions-for-use portal, and a whistleblower reporting system.

Differentiator

Problem solved

Functional benefit

Brands

• MULTI: Dietary supplements brand including MULTIvitD3 Baby, MULTIvitDK, MULTIprosti, and FOLMIT forte products.

Quantifiable outcome

• 13 million drug packages delivered to Austrian patients in 2023
• +2 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators5 records

Recent moves1 record

Expansion highlights5 records

Direct peers

• KRKA: Slovenian-headquartered generics manufacturer with strong Central and Southeastern European presence. Closely comparable to Genericon in scale, therapeutic breadth, pharmacy-driven distribution model, and CEE regional footprint including Croatia.
• Gedeon Richter: Hungarian pharmaceutical company with a substantial generics portfolio across cardiovascular, CNS, and women's health, plus a CEE distribution footprint. Operates a pharmacy-led model in Austria and neighboring markets similar to Genericon.
• ratiopharm (Teva): German generics brand owned by Teva with deep Austrian pharmacy penetration under the ratiopharm and ABDA-aligned brands. Direct competitor to Genericon across multiple therapeutic areas in the same Austrian pharmacy channel.
• Hexal (Sandoz): German generics brand owned by Sandoz with strong Austrian market presence through pharmacy distribution. Directly competes with Genericon across cardiovascular, CNS, and metabolic therapy areas in Austrian retail pharmacy channels.
• TAD Pharma: German specialty generics company focused on niche therapeutic areas including urology, neurology, and psychiatry — categories that overlap directly with Genericon's strongest franchises. Operates in Austrian pharmacy distribution channels.

Broad incumbents

• STADA Arzneimittel: European-focused generics and consumer healthcare company with broad specialty, generics, and OTC portfolios across the DACH and CEE region. Operates as a scaled incumbent in Genericon's core markets and competes directly in Austrian pharmacy channels.
• Sandoz: Global generics leader (Novartis spin-off) with deep penetration across European markets including Austria. Competes with Genericon across virtually all therapeutic categories with significantly greater scale and cost-of-goods advantages.
• Teva Pharmaceutical Industries: World's largest generics manufacturer with extensive European footprint including Austria through legacy ratiopharm branding. Competes directly with Genericon in the Austrian pharmacy channel across most therapeutic categories.

Regional players

• Egis Pharmaceuticals: Hungarian-headquartered generics and specialty pharmaceutical company with CEE regional focus. Comparable therapeutic breadth and pharmacy distribution model, with overlapping presence in Austria and Croatia.
• Polpharma: Polish generics manufacturer with growing Central European footprint. Comparable scale and therapeutic portfolio breadth, competing in overlapping CEE pharmacy channels and increasingly active in Austria and neighboring markets.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Genericon Pharma